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acute type B aortic dissection treated by implantation of a stent graft:
a single-center report
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Background: Background: Stent grafting for treatment of type B aortic dissection has
been extensively used. However, the difference in the long-term clinical outcome
between patients with chronic versus acute type B aortic dissection remains unknown.
This study aimed to analyze the difference in long-term clinical outcome after
endovascular repair for patients with chronic ($2 weeks) versus acute (<2 weeks) type
B aortic dissection.
Methods: Between May 2000 and June 2011, a total of 174 patients with type B aortic
dissection (56 chronic, 118 acute) treated by endovascular repair were studied
prospectively. Follow-up three-dimensional computed tomography scanning and
aortoangiography were scheduled at 3–6 months after the index procedure. Propensity
score matching was used to compare the difference in the endpoint between the two
groups.
Results: The procedure-related event rate was 18.6% in the acute group and 5.4% in
the chronic group (P ¼ 0.021), but this difference became nonsigniﬁcant after
propensity score matching. At the end of follow-up (mean 2.49 years), overall and
aorta-related mortality was 11.0% and 7.6%, respectively, in the acute group, and was
not signiﬁcantly different from that in the chronic group (3.6% and 3.6%, P ¼ 0.148
and P ¼ 0.506, respectively). Both false and true lumina showed signiﬁcant remod-
eling over time, with .93% complete false-lumen thrombosis. Untreated tear and type I
endoleak were predictors of clinical events during follow-up.
Conclusions: Comparable long-term clinical results were achieved in patients with
chronic or acute type B aortic dissection after implantation of a stent graft.
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Background: Transcatheter aortic valve replacement (TAVR) via the transfemoral
(TF) approach is currently performed by both open surgical and percutaneous access.
Vascular complications are associated with morbidity and mortality, but few studies
have directly compared access approach.
Methods: Data was collected on all patients undergoing TF TAVR with Sapien or
Sapien XT aortic bioprostheses (Edwards Inc., Irvine, CA) between November 2007
and April 2013 at our institution. Valve Academic Research Consortium deﬁnitions
were utilized.
Results: TF TAVR was performed in 331 patients via an open surgical (n¼120) or
percutaneous (n¼211) approach. Both groups were similar in age, however the open
group had a greater incidence of cardiovascular comorbidities. The average sheath
outer diameter (OD) was slightly larger in the open group as compared to the
percutaneous group (8.6  0.4 vs. 8.4  0.6 mm, p<0.001). There were fewer major
vascular complications in the percutaneous as compared to the open group (11% vs.
20%, p¼0.03), and a trend toward fewer overall vascular complications (17% vs.
26%, p¼0.06). More patients with vascular complications in the percutaneous cohort
had minimal artery diameter (MAD) less than sheath OD (74% versus 55%, p¼0.03).
The percutaneous group had decreased length of stay (LOS) compared to the open
group (7.5  4.7 vs. 9.9  9.9 days, p¼0.003). There was no difference in in-hospital
mortality between the open and percutaneous groups (2.5 % vs. 1 %, p¼0.36). The use
of second generation TAVR sheaths and valves via a percutaneous approach was
associated with an even greater reduction in vascular complications (8% vs. 25%,B226 JACC Vol 62/18/Suppl B j October 27–Novemberp¼0.01) and LOS (7.0  4.8 versus 10.1  10.0 days, p¼0.04) as compared to the
open group with ﬁrst generation devices. Despite an increase in the difference between
sheath OD and MAD (-0.21 vs. 0.27 mm, p¼0.02) in the ﬁrst and second half of our
percutaneous access experience, the rates of vascular complications did not change
over this time.
Conclusions: TF TAVR via a percutaneous approach is associated with less vascular
morbidity and lower LOS as compared to an open surgical approach. These beneﬁts
are even greater with second-generation (Sapien XT) devices.
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Background: Valve academic research consortium (VARC) guidelines were devised
in an effort not only to standardize clinical endpoint deﬁnitions but also to select
endpoints that best reﬂect the safety and efﬁcacy of transcatheter aortic valve
replacement (TAVR). These guidelines are evolving in an expert led manner. We
sought to compare the predictive value for survival of major vascular complications
(VC) by VARC-1 and 2 deﬁnitions.
Methods: A large single center series of patients undergoing TAVR by multiple
approaches were studied. We deﬁned VC according to VARC-1 and VARC-2 deﬁ-
nition, and compared the mortality one year after the procedure. Data was analyzed
using Kaplan-Meier (KM) and Cox regression multivariable models that included all
variables related to 1-year mortality to a signiﬁcance level0.1.
Results: Data was analyzed for 388 patients. KM curves showed a numerically lower
survival rate at 1-year by major VC with both deﬁnitions, but only VARC-2 had
statistical signiﬁcance; 79.2% vs. 60.7% with VARC-2 (p ¼0.015), and 78.8% vs.
70.5% with VARC-1 (p ¼ 0.211). Cox regression multivariable model showed VC by
VARC-2 deﬁnition to be an independent predictor of 1-year mortality (p ¼ 0.004), but
not when VC was substituted by the VARC-1 deﬁnition (p¼0.08).
Conclusions: The VARC-2 deﬁnition for vascular complications offers better strati-
ﬁcation of survival than the VARC-1 deﬁnition, supporting its widespread use.
Reasons for this important difference will be discussed.TCT-744
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Background: Although prior studies describe the ﬂuoroscopic operator-independent
motion of the balloon-expandable valve, no studies have described the trans-
esophageal echocardiogram (TEE) appearance of valve deployment.
Methods: Intraoperative TEE from 100 consecutive* patients presenting for TAVR
were retrospectively analyzed. Patients with unreliable pacemaker capture or obvious
operator-induced device motion during deployment were excluded (n¼16). Device
position was deﬁned as the percent of total device height below the virtual annulus
(hinge points of aortic valve cusps). Device position was measured pre-deployment
(during rapid pacing) and post-deployment. Device cranial movement during
deployment was deﬁned as the difference between the pre-deployment and post-
deployment position (in mm) of the valve midpoint.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
